CSIMarket
 
Icosavax Inc   (ICVX)
Other Ticker:  
 
 
Price: $15.3100 $-0.14 -0.906%
Day's High: $15.44 Week Perf: -0.65 %
Day's Low: $ 15.28 30 Day Perf: -1.73 %
Volume (M): 9,315 52 Wk High: $ 16.10
Volume (M$): $ 142,616 52 Wk Avg: $9.51
Open: $15.40 52 Wk Low: $4.75



 Market Capitalization (Millions $) 766
 Shares Outstanding (Millions) 50
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -97
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 5

Icosavax Inc
Icosavax Inc is a biotechnology company that focuses on the development of vaccines for infectious diseases. The company uses a proprietary virus-like particle (VLP) technology to create safe and effective vaccines. Their vaccines are designed to mimic the structure and characteristics of the target virus to stimulate a robust immune response. Icosavax Inc aims to address global health challenges by developing vaccines for diseases such as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), which currently have limited treatment options. The company has a strong emphasis on research and development and collaborates with academic institutions and industry partners to advance their vaccine candidates.


   Company Address: 1930 Boren Avenue Seattle 98101 WA
   Company Phone Number: 737-0085   Stock Exchange / Ticker: NASDAQ ICVX
   ICVX is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Merger and Acquisition

AstraZeneca Strengthens Late-Stage Vaccine Pipeline with Acquisition of Icosavax: Paving the Way for Breakthrough RSV and hMPV Combination Vaccine

Published Tue, Dec 12 2023 12:00 PM UTC



In a significant move to bolster its position in the biopharmaceutical arena, AstraZeneca has recently announced its definitive agreement to acquire Icosavax, Inc. The Delaware-based clinical-stage biopharmaceutical company has gained recognition for its cutting-edge protein virus-like particle (VLP) platform, which has shown great promise in the development of dif...

Clinical Study

Big Step Forward in Respiratory Virus Prevention: Icosavax?s Landmark Phase 2 Vaccine Results Promising for Older Adults' Protection.

Published Tue, Dec 12 2023 7:00 AM UTC


In the pursuit of the ultimate way to combat RSV and hMPV, the combination VLP vaccine, IVX-A12, is a blend of two vaccines previously being developed separately ?? the IVX-RSV and the IVX-hMPV. The combination of these two has shown promising results in interim Phase 2, thereby justifying the move towards a combined vaccine.
Phase 2 trials, which involve hundreds ...

Icosavax Inc

CFO Implements Strategic Initiatives to Overcome Operating Shortfall and Drive Growth at Icosavax Inc in Q3 2023


As the biotechnology and pharmaceutical sector continues to be driven by bellwether companies, it is crucial not to overlook the smaller players in the industry. One such company, Icosavax Inc, has recently shared their financial results for the third quarter of 2023. While the operating shortfall of $-25.275 million is cause for concern, there are signs of hope for shareholders and potential revenue sources on the horizon.
Despite the current focus being on Icosavax Inc's lack of proficiency at the ICVX, shareholders remain optimistic about the company's future. They eagerly anticipate the introduction of new revenue streams in the near future, which could steer the organization towards growth and financial stability. To achieve this, the CFO is implementing various corporate policies aimed at establishing a steady product line.

Icosavax Inc

Icosavax Inc faces growing business costs and revenue concerns as operating shortfall widens in Q2 2023



In the Biotechnology & Pharmaceuticals industry, industry experts have begun closely examining the financial performance of companies in the second quarter of 2023. Attention has turned to Icosavax Inc as it reports an operating shortfall of $-28.955 million, with no mention of revenue for the reporting season spanning April to June 30, 2023. This absence of revenue has raised apprehensions among investors, who are eagerly anticipating the emergence of new revenue streams.
While investors focus on revenue generation, the current organizational and operational excellence of the Biotechnology & Pharmaceuticals company seems to have taken a backseat among shareholders' concerns.
The most significant revelation from the fiscal time-frame ending June 30, 2023, is the net loss of $-26.497 million, marking a significant increase from the $-22.636 million loss reported during the same period in the previous year. This amplified net loss further intensifies the scrutiny surrounding Icosavax Inc's financial performance.

Icosavax Inc

Icosavax Inc Continues to Struggle with Consistent Losses, Surpassing Previous Deficits in Financial Period Ending March 31, 2023

The latest financial report released by Icosavax Inc does not paint a pretty picture for investors. The company's financial period ending on March 31, 2023, showed a continued trend of consistent losses. The company lost $0.60 per share compared to the same period a year ago, where it lost the same amount. Further exacerbating the situation, the deficit increased from $0.44 per share in the previous reporting period.
Icosavax Inc revenues also did not show any signs of improvement, remaining stagnant at $0.00 million compared to $0.58 million in the same reporting period a year before, and there was no noticeable sequential increase. The situation implies that the company is struggling to find any potential growth drivers to improve the trajectory of their finances.
To add to these woes, Icosavax Inc realized a net deficit of $-24.561 million during the financial period ending March 31, 2023, which is a significant increase compared to the prior year, where the deficit was $-23.533 million. Investors are, therefore, wary that this trend may continue in the near-term.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com